

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	ETROLIZUMAB
PRONUNCIATION	et" roe liz' oo mab
THERAPEUTIC CLAIM	Treatment of inflammatory bowel disease (IBD)

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human integrin  $\alpha 4\beta 7$ /integrin  $\alpha E\beta 7$ ) (human-rat monoclonal rhuMAb Beta7 heavy chain), disulfide with human-rat monoclonal rhuMAb Beta7 light chain, dimer
2. immunoglobulin G1, anti-(human integrin alpha-4/beta-7 (Peyer patches-specific homing receptor LPAM-1) and human integrin alpha-E/beta-7 (HML-1 antigen)); humanized rat monoclonal rhuMAb Beta7 des-447-lysine(CH3<sup>107</sup>K)- $\gamma 1$  heavy chain (220-214')-disulfide with humanized rat monoclonal rhuMAb Beta7  $\kappa 1$  light chain, dimer (226-226":229-229")-bisdisulfide

MOLECULAR FORMULA	C <sub>6396</sub> H <sub>9874</sub> N <sub>1702</sub> O <sub>2010</sub> S <sub>42</sub>
MOLECULAR WEIGHT	144.1 kDa (peptidic part)
TRADEMARK	None as yet
MANUFACTURER	Genentech
CODE DESIGNATION	rhuMAb Beta7, Anti-beta7, PRO145223
<u>CAS</u> REGISTRY NUMBER	1044758-60-2